Neurogene (NGNE) vs Silence Therapeutics Plc American Depository Share (SLN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Silence Therapeutics Plc American Depository Share (SLN) has outperformed Neurogene (NGNE) over the past year, gaining 81.3% versus a gain of 2.6%. Over five years, SLN leads with a -56.4% price change compared with -81.6% for NGNE. Silence Therapeutics Plc American Depository Share is the larger company by market cap ($591.7 million vs $530.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NGNE | SLN |
|---|---|---|
| Share price | $26.50 | $9.52 |
| Market cap | $530.30M | $591.71M |
| 1-day change | +2.44% | -3.05% |
| YTD return | +28.64% | +56.58% |
| 1-year return | +2.59% | +81.33% |
| 5-year return | -81.65% | -56.37% |
| EPS (TTM) | $-5.04 | $-1.29 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $43.66 | $17.58 |
| 52-week low | $15.93 | $4.19 |
| Distance from 52-week high | -39.30% | -45.84% |
| Analyst consensus | none | buy |
| Avg. price target upside | +193.89% | +246.64% |
| Average volume | 247.13K | 1.12M |
| Shares outstanding | 20.01M | 62.15M |
| Employees | 131 | 88 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLN has outperformed NGNE by 78.7 percentage points over the past year.
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Healthcare · Biotechnology · 131 employees
About Silence Therapeutics Plc American Depository Share
SLN stock →Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Healthcare · Biotechnology · 88 employees
NGNE vs SLN FAQ
Which is bigger, Neurogene or Silence Therapeutics Plc American Depository Share?
Silence Therapeutics Plc American Depository Share (SLN) is larger, with a market capitalization of $591.71M compared with $530.30M for Neurogene (NGNE).
Which stock has performed better over the past year, NGNE or SLN?
SLN returned +81.33% over the past 12 months, compared with +2.59% for NGNE (price return, excluding dividends). Past performance does not predict future results.
Are Neurogene and Silence Therapeutics Plc American Depository Share in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.